Atlas Trials

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Clinical trial NCT04363255 · UNKNOWN

Trial details

NCT number
NCT04363255
Sponsor
Taizhou Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Carcinoma
Start date
2020-05-01
Primary completion
2022-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.